San Francisco, CA – December 12, 2023 – A groundbreaking new study, the first phase of the WISDOM study, has unveiled compelling evidence suggesting a revolutionary shift in breast cancer screening practices. The research indicates that moving away from a uniform, age-based approach to a personalized, risk-stratified strategy can lead to more effective detection and prevention, ultimately proving safer for women. The findings, based on data from 46,000 women across the United States, challenge decades of established guidelines and advocate for a future where screening frequency is precisely matched to an individual’s unique risk profile.
Published on December 12th in the prestigious journal JAMA and simultaneously presented at the San Antonio Breast Cancer Symposium, the study’s results represent a pivotal moment in the ongoing battle against breast cancer. By meticulously tailoring screening intervals and modalities to personal risk levels, researchers demonstrated the potential to significantly reduce the incidence of advanced cancer diagnoses, ensuring that individuals receive the most appropriate level of surveillance without unnecessary intervention.
The Imperative for Change: Beyond Age-Based Guidelines
For decades, breast cancer screening guidelines have largely relied on a one-size-fits-all model, predominantly dictating screening frequency based on age. The assumption underpinning this approach was a relatively uniform risk across the female population within specific age brackets. However, as scientific understanding of breast cancer evolution and individual susceptibility has grown, this generalized framework has increasingly shown its limitations.
"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," asserted Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. Her remarks underscore the profound implications of the WISDOM study. Dr. Esserman emphasized, "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."
Breast cancer remains the most frequently diagnosed cancer among women in the United States, excluding non-melanoma skin cancers. Despite its prevalence, it has long been understood that an individual woman’s risk of developing the disease can vary dramatically. Factors ranging from genetic predispositions and family history to breast density, hormonal influences, and lifestyle choices all contribute to a complex risk landscape that traditional age-based guidelines have largely failed to address comprehensively. The WISDOM study’s premise was to directly tackle this variability, aiming to create a screening paradigm that is as unique as each patient it serves.
Chronology of a Transformative Study
The WISDOM study, an acronym for Women Informed to Screen Depending On Measures of Risk, was conceived with the ambitious goal of directly comparing the efficacy and safety of traditional annual mammography against a novel, individualized risk-based screening strategy. UCSF, a globally recognized leader in medical research and patient care, served as the coordinating center for this monumental endeavor, spearheading its design, execution, and analysis.
The initial phase of the study, the results of which have just been unveiled, encompassed a substantial cohort of 46,000 women recruited from various sites across the United States. Enrollment for the broader WISDOM initiative commenced in 2016, with researchers meticulously gathering a comprehensive array of data points from participants. This included not only demographic information but also detailed medical histories, lifestyle questionnaires, and crucially, genetic samples for advanced analysis.
The presentation of these pivotal results at the San Antonio Breast Cancer Symposium, a premier international gathering for breast cancer researchers and clinicians, marked a significant milestone. The simultaneous publication in JAMA, one of the world’s most widely circulated general medical journals, ensures that these findings reach a broad audience of healthcare professionals and policymakers, paving the way for their eventual integration into clinical practice.
The WISDOM study is not a static endeavor; it is an evolving research program. Following the successful completion of this initial phase, researchers are now actively refining their risk assessment models through the WISDOM 2.0 study, which is currently enrolling participants. This ongoing work aims to further enhance the precision with which women at higher risk of aggressive breast cancers can be identified, ensuring they receive truly individualized screening and prevention strategies tailored to their long-term health needs.
Supporting Data: The Mechanics of Personalized Screening
The core innovation of the WISDOM study lies in its sophisticated approach to individual risk assessment. Instead of a blanket recommendation, researchers employed well-validated risk models to classify participants into distinct categories, moving beyond simple age-based criteria. These models integrated a comprehensive suite of factors, including:
- Age: While not the sole determinant, age remained a crucial component in the overall risk calculation.
- Genetic Information: This encompassed not only screening for known high-risk variants like BRCA1 and BRCA2 but also evaluating a broader spectrum of smaller DNA changes combined into a polygenic risk score (PRS).
- Lifestyle Factors: Habits such as diet, physical activity levels, alcohol consumption, and smoking history were factored into the risk equation.
- Health History: Personal and family history of breast cancer, previous benign breast biopsies, and other relevant medical conditions contributed to the assessment.
- Breast Density: A significant independent risk factor, breast density was also incorporated into the personalized risk models.
Based on this multi-faceted evaluation, participants were assigned to one of four risk categories, each with a tailored screening recommendation:
- Lowest Risk Group (26% of participants): These women were advised to delay screening until age 50 or until an advanced algorithm indicated their individual risk had naturally reached that of a typical 50-year-old woman. This approach aims to reduce unnecessary screening, minimizing radiation exposure and the anxiety associated with false positives.
- Average Risk Group (approximately 62% of participants): For this majority, the recommendation was to undergo screening every two years, aligning with existing guidelines for many women in this demographic but now supported by a more granular risk assessment.
- Elevated Risk Group (8% of participants): Women in this category were advised to receive annual mammograms, a more intensive screening schedule deemed appropriate for their increased risk profile.
- Highest Risk Group (2% of participants): This cohort, identified as facing the most significant risk, was recommended to undergo screening twice a year. Their protocol involved alternating between mammography and magnetic resonance imaging (MRI), regardless of their age. This intensified surveillance strategy is designed to detect cancers at their earliest, most treatable stages in this vulnerable population.
Crucially, the study demonstrated that this personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This finding directly refutes concerns that a less frequent screening schedule for lower-risk women might result in missed cancers. Instead, it suggests that resources were effectively reallocated, intensifying screening where it was most needed without compromising overall detection rates. The strong acceptance of this personalized model was further highlighted by the fact that among women who chose not to be randomized into the study arms but joined an observational group, a remarkable 89% opted for the risk-based screening strategy, signaling strong public receptivity to this innovative approach.
Personalized Prevention for Higher-Risk Women
Beyond tailored screening schedules, the WISDOM study also introduced a critical component of personalized prevention for participants identified as having elevated or highest risk. This proactive strategy aimed not just to detect cancer early but to actively lower the chances of its development. Support for these women included:
- Online Decision-Making Tools: Access to specialized online resources focused on breast health, empowering women with information and aiding in informed decision-making regarding their preventive care.
- Direct Contact with Breast Health Specialists: Personalized guidance and counseling from experts, offering a direct channel for questions, concerns, and tailored advice.
- Lifestyle Modifications: Recommendations covered evidence-based lifestyle changes, such as improving dietary habits to include more fruits, vegetables, and whole grains, and increasing physical activity to maintain a healthy weight. These factors are known to influence breast cancer risk.
- Pharmacological Interventions: Discussions about specific medications known to help reduce breast cancer risk for certain high-risk individuals, providing an opportunity for informed choices about chemoprevention.
This holistic approach, integrating both enhanced surveillance and active prevention, represents a significant advancement in patient care. Dr. Jeffrey A. Tice, MD, a UCSF professor of Medicine and co-author of the study, underscored the efficiency of this model. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," he stated, highlighting the strategic allocation of healthcare resources to maximize impact.
Expanding Genetic Testing Beyond Family History
One of the most profound and potentially practice-changing findings of the WISDOM study pertains to genetic testing. Historically, genetic screening for breast cancer susceptibility genes like BRCA1 and BRCA2 has been largely restricted to individuals with a strong family history of the disease or specific clinical criteria. The WISDOM study, however, adopted a more inclusive approach, offering genetic testing to all enrolled women, regardless of their family history.
The results were striking: a significant 30% of women who tested positive for a pathogenic genetic variant linked to a higher breast cancer risk reported absolutely no family history of the disease. Under current clinical guidelines, a substantial proportion of these women would not have qualified for genetic testing and would therefore remain unaware of their elevated risk, potentially delaying appropriate surveillance or preventive measures. This finding strongly advocates for a re-evaluation of current genetic testing criteria, suggesting a broader, population-based approach could identify a critical cohort of at-risk individuals currently missed by the system.
Furthermore, the study extended its genetic analysis beyond well-known pathogenic variants. Researchers also evaluated smaller DNA changes that, when combined, form a "polygenic risk score" (PRS). A PRS aggregates the effects of numerous common genetic variants, each individually contributing a small amount to overall risk, but together providing a more nuanced and precise estimate of an individual’s genetic predisposition. This sophisticated approach significantly improved the precision of risk predictions and, notably, resulted in 12% to 14% of participants being reassigned to a different risk category based on their comprehensive genetic profile.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," noted Allison S. Fiscalini, MPH, of UCSF, who serves as director of the Athena Breast Health Network and the WISDOM study. Fiscalini emphasized the transformative potential: "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." The inclusion of PRS alongside established genetic markers marks a significant leap forward in understanding individual susceptibility and refining risk stratification.
Official Responses and Expert Perspectives
The overwhelming sentiment from the research team and the broader medical community regarding the WISDOM study’s initial findings is one of profound optimism and recognition of its transformative potential.
Dr. Laura J. Esserman, as the lead author and a long-time advocate for personalized medicine in breast cancer, articulated the study’s impact with conviction. Her call for a fundamental alteration of clinical guidelines and practice stems from the clear advantages demonstrated by the risk-based approach. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies," she reiterated, emphasizing the holistic nature of the proposed new paradigm. Her vision extends beyond merely detecting cancer to actively preventing it where possible, particularly for those identified as high-risk.
Dr. Jeffrey A. Tice highlighted the pragmatic benefits of this strategy, focusing on efficiency and resource allocation. His observation that "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer" speaks to the public health implications. In an era of escalating healthcare costs and finite resources, optimizing screening protocols to deliver maximum benefit to those who need it most represents a fiscally responsible and clinically sound strategy. This efficiency allows for more intensive, potentially life-saving interventions for high-risk individuals, while reducing unnecessary anxiety, biopsies, and radiation exposure for those at lower risk.
Allison S. Fiscalini, representing the operational backbone of the WISDOM study, emphasized the pioneering nature of its genetic testing component. Her statement that this is "one of the first studies to offer genetic testing to all women, regardless of family history" underscores a critical methodological departure from traditional practice. The revelation that a substantial portion of women with high-risk genetic variants lack a family history is a powerful testament to the necessity of broadening genetic screening. Fiscalini’s foresight that these results "could have a real impact on improving the safety and effectiveness of screening and prevention" reflects the study’s potential to redefine standard care.
Collectively, these expert responses paint a picture of a medical community ready to embrace evidence-based change. The convergence of clinical effectiveness, resource efficiency, and enhanced patient safety presented by the WISDOM study creates a compelling case for a paradigm shift in how breast cancer screening is approached globally.
Implications: Shaping the Future of Breast Cancer Care
The findings of the WISDOM study carry profound implications for the future of breast cancer screening, prevention, and public health policy. They strongly advocate for a fundamental re-evaluation of existing national and international screening guidelines, which have largely remained tethered to age-centric recommendations.
1. Revolutionizing Clinical Guidelines: The most immediate implication is the potential for national and international health organizations to revise their breast cancer screening guidelines. If adopted, these new guidelines would move away from rigid age-based schedules toward a more dynamic, individualized risk assessment. This shift would empower healthcare providers to make more informed, patient-specific recommendations, leading to a more nuanced and effective screening landscape.
2. Enhancing Patient Safety and Experience: For lower-risk women, a personalized approach means fewer unnecessary mammograms, reducing cumulative radiation exposure and the psychological burden of false positives, which often lead to anxiety and avoidable follow-up procedures like biopsies. For higher-risk women, it means earlier, more intensive screening, potentially leading to earlier detection of aggressive cancers when they are most treatable, thereby improving survival rates and quality of life. The study’s confirmation that personalized screening did not increase late-stage diagnoses is crucial in this regard.
3. Advancing Precision Medicine: The WISDOM study is a powerful testament to the growing field of precision medicine. By integrating genetic, biological, and lifestyle data, it exemplifies how a detailed understanding of individual variability can lead to tailored interventions that are superior to one-size-fits-all approaches. This sets a precedent for how other areas of cancer screening and disease prevention might evolve.
4. Expanding Access to Genetic Information: The discovery that a significant percentage of women with high-risk genetic variants have no family history of breast cancer highlights a critical gap in current genetic testing protocols. This finding could lead to broader, perhaps even universal, genetic screening for breast cancer susceptibility genes, ensuring that more women are aware of their true risk and can take appropriate preventive measures. This could also drive down the cost of genetic testing through increased demand and technological advancements.
5. Optimizing Resource Allocation: The study’s emphasis on efficiency and redirecting resources from lower-risk to higher-risk individuals has significant economic implications for healthcare systems. By avoiding unnecessary screenings and interventions for a large segment of the population, resources can be strategically reallocated to provide more intensive, potentially life-saving care for those who truly need it, leading to a more sustainable and equitable healthcare model.
6. The Road Ahead: WISDOM 2.0 and Beyond: The ongoing WISDOM 2.0 study signifies the continuous commitment to refining these risk assessment models. The goal is to further enhance the ability to identify women at higher likelihood of developing aggressive breast cancers, ensuring they receive the most advanced and effective screening and prevention strategies available. This iterative process of research and refinement is crucial for the long-term success and widespread adoption of personalized breast cancer screening.
The WISDOM study represents more than just a new set of data; it heralds a fundamental evolution in our approach to breast cancer. By embracing the complexity of individual risk, it promises a future where screening is not just routine, but truly personalized, safer, and ultimately, more effective in saving lives.
About the WISDOM Study
The WISDOM study is a multi-institutional effort coordinated by UCSF, with significant contributions from investigators at UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, Weill Cornell Medicine in New York, and the Karolinska Institutet in Stockholm.
Key authors from UCSF include Laura J. Esserman, MD, MBA; Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD. Allison S. Fiscalini, MPH, serves as director of the Athena Breast Health Network and the WISDOM study.
The study received significant funding support from the Patient-Centered Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among other contributing sources detailed in the JAMA publication.
Conflicts of Interest: Dr. Laura J. Esserman is a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource. Comprehensive disclosures for all investigators are available in the published paper.
About the Author
